This is a preview of subscription content, log in via an institution to check access.
Références
GROSS V., ANDUST T., CAESAR I., MANNS M., LOCHS H., GENSER D., MAY B., SCHULTZ H-J., BAR U., UBERSCHAER B., WEBER A., GIEREND M., EWE K. and SCHOLMERICH J., GIEREND M. — Regensburg, Mainz and Geretsried, Germany. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. 1610
CAMPIERI M., FERGUSON A., DOE W. and the International Budésonide Study Group. Bologna, Italy; Edinburgh, Scotland and Canberra, Australia. — Oral budesonide competes favorably with prednisolone in active Crohn’s disease. 2927.
SANDBORN W.J., TREMAINEW.J. and LAWSON G.M. Rochester, MN. — Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn’s disease treated with high dose oral cyclosporine. 2467.
SANDBORN W.J., VAN OS E.C., ZINS B.J., W.J. TREMAINE, D.C. MAYS and LIPSKY J.J. Rochester, MN. — An intravenous loading dose of azathioprine decreases the time to response in patients with inflammatory and fistulous Crohn’s disease. 2926.
EMMRICH J., SEYFARTH M., LIEBE S. AND EMMRICH F. ROSTOCK, LUEBECK and Leipzig, Germany. — Anti-CD4 antibody treatment in inflammatory bowel disease without a long CD4 + cell depletion. 1942.
CHEETHAM B.C. and HARRIS M.S. Milwaukee, WI. — Efficacy and safety of subcutaneous methotrexate in Crohn’s disease: a preliminary report. 2471.
GRAHAM D.Y., AL-ASSI M.T. and ROBINSON M. Houston, TX and Oklahoma City, OK. — Prolonged remission in Crohn’s disease following therapy for Mycobacterium paratuberculosis infection. 2930.
GREENBLOOM S.L., STEINHART A.H. and GREENBERG G.R. — Toronto, Canada. Ciprofloxacin and métronidazole: combination antibiotic therapy for ileocolonic Crohn’s disease. 2453.
SCHREIBER S., HAMLING S., LOCHS H. AND READLER A. HAMBURG and Berlin, Germany — Prospective pilot trial of systemic 4-aminosalicylate therapy for acute Crohn’s disease. 1941.
COLLINS C.E., FORBES A. and Rampton D.S. London, UK. — Anti-platelet therapy in active Crohn’s disease: an open trial using picotamide, a thromboxane antagonist.1937.
GREENBERG G.R., FEAGAN B.G., MARTIN F., SUTHERLAND L.R., THOMSON A.B.R., WILLIAMS C.N., NILSSON L.G., PERSSON T. and the Canadian Inflammatory Bowel Disease Study Group. Toronto. Canada. — Oral budesonide as maintenance treatment for Crohn’s disease. 800.
BELLUZZI A., BRIGNOLA C., CAMPIERI M., PERA A., CAMPORESI E., BOSCHI S., RIZZELLO F., BELLOLI C., DE SIMONE G., ASTEGIANO M., GIONCHETTI P., MIGLIOLI M. and BARBARA L. Hospital BO and Hospital TO, Italy. — New fish oil derivative for preventing clinical relapses in Crohn’s disease: a double blind placebo controlled randomized trial. 799.
MODIGLIANI R., COLOMBEL J.F., DUPAS J.L., DAPOIGNY M., BOUHNIK Y., VEYRAC M., CAGIOT G., DUCLOS B., SOULÉ J.C., GENDRE J.P., DANNE O. and MARY J.P. Paris, France. — Mesalamine in Crohn’s disease patients with prednisolone-induced remission: effect on steroid weaning and remission maintenance in the year after weaning. A placebo-controlled, multicenter double-blind trial. 2475.
SUTHERLAND L.R., MARTIN F., BAILEY R.J., FEDORAK R., DALLAIRE C., ROSSMANN R., POLESKI M., HARVEY M. and LARIVIERE L. Calgary, Canada. — 5-aminosalicylic acid (Pentasa) in the maintenance of remission of Crohn’s disease. 2929.
BERTRAN X., FERNANDEZ-BANARES F., ESTEVE M., HUMBERT P., PLANAS R. and GASSULL M.A. Badalona, Spain. — Usefulness of azathioprine to maintain cyclosporine (Cy-A) -induced remission in severe steroid-refractory inflammatory bowel disease. 2468.
HANAUER S. and ROBINSON M. Chicago, IL and Oklahoma City, OK. — Dose ranging study of budesonide enema in active distal ulcerative colitis. 611.
BAYLESS T. and SNINSKY C. Baltimore, MD and Gainesville, FL. — Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis. 2928.
STEINHART A.H., HIRUKI T., BRZEZINSKI A. and BAKER J.P. Toronto, Canada. — Treatment of left-sided ulcerative colitis with butyrate enemas: a randomized controlled trial. 3511.
SAFDI M., DEMICCO M., SNINSKY C., BANKS P., WRUBLE L., DEREN J., KOVAL G., NICHOLS T., TARGAN T., TAYLOR D., FLEISHMANN C. and NESTER T. Marietta, GA. — A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. 1612.
MADSEN K.L., TAVERNINI M.M. and FEDORAK R.N. — Edmonton, Canada. Interleukin-10 stimulates ion absorption in mammalian small intestine. 1260.
SCHREIBER S., REINKING R., PANZER U., HEINIG T. AND READLER. A. HAMBURG and Berlin, Germany. — Interleukin-10 downregulates IBD mononuclear phagocyte activationin vitro andin vivo. 1261.
D’ALBASIO G., PACINI F., CAMARRI E., TRALLORI G., BARDAZZI G., BONANOMI A., MILLA M., FERRERO S., BIAGINI M. and QUARANTA S. Florence, Grosseto and Castelfiorentino, Italy. — Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: results at 12 months. 1613.
MOSLEY R. MG., MADSEN J., REICHELDERFER M. and HARMS B.A. Madison, WI. — Does preoperative ileitis predispose to pouchitis? 636.
VALLEUR P., POUPARD B., PANIS Y., GALIAN A and HAUTEFEUILLE P. Paris, France. — Ileal pouch-anal anastomosis for Crohn’s disease. 3534.
JYOTHEESWARAN S., PENMETSA P., PARK J.S., SHAH A.N., STORMONT J.M. and CHEY W.Y. Rochester, NY. — Has 6-mercatopurine therapy in inflammatory bowel disease changed the clinical outcome and reduced the incidence of surgeries? 623.
Author information
Authors and Affiliations
About this article
Cite this article
Lévy, P. Thérapeutique des MICI. Acta Endosc 25 (Suppl 2), 219–222 (1995). https://doi.org/10.1007/BF02970179
Issue Date:
DOI: https://doi.org/10.1007/BF02970179